HIGHLIGHTS
- who: Qingli Cui from the University of Miami, United States have published the article: Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer, in the Journal: (JOURNAL)
- what: In this study, all outcomes were compared between apatinib plus PD-1 mAb and apatinib or PD-1 mAb monotherapy. This study has several limitations that should be considered.
- future: Largescale prospective studies are required to determine the clinical efficacy and safety of apatinib plus PD-1 mAb.
SUMMARY
In a phase 2 study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.